VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | 5-year follow-up of ECHELON-2: A+CHP vs CHOP for CD30+ PTCL

Steven Horwitz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the 5-year results of the double-blind Phase III ECHELON-2 study (NCT01777152). This study is an active comparator trial comparing the efficacy and safety of brentuximab vedotin in combination with CHP (A+CHP) with the current standard-of-care, the CHOP regimen, for patients with CD30-positive peripheral T-cell lymphoma (PTCL). A total of 452 patients with previously untreated PTCL were randomized to A+CHP or CHOP for six or eight cycles. The results presented here indicate that at an extended follow-up time of 5-years, compared to CHOP, frontline treatment with A+CHP continues to provide significant improvements in progression-free survival (PFS) and overall survival (OS), as seen at 3-years follow-up. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Dr Horwitz has received research support for clinical trials from ADC Therapeutics, Affimed, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium /Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem. He has consulted, received honorarium from, or participated in advisory boards for; ADC Therapeutics, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, Seattle Genetics, Takeda, Trillium Therapeutics, Verastem, and Vividion Therapeutics.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter